XML 32 R23.htm IDEA: XBRL DOCUMENT
v3.4.0.3

Significant Accounting Policies - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2012 | Mar. 31, 2016 USD ($) Tranche Segment shares | Mar. 31, 2015 USD ($) shares | Dec. 31, 2015 USD ($) shares | Nov. 30, 2015 USD ($) | Mar. 05, 2015 USD ($) | Dec. 31, 2014 shares | May. 31, 2014 USD ($) | Dec. 31, 2012 USD ($) | Dec. 06, 2012 USD ($)
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Sales discount percentage |  | 2.00% |  |  |  |  |  |  |  |
Sales discount term |  | 30 days |  |  |  |  |  |  |  |
Trade receivables, credit period |  | 30 days |  |  |  |  |  |  |  |
Number of tranches for private placement transaction | Tranche |  | 2 |  |  |  |  |  |  |  |
Accounts receivable written off |  | $ 0 |  |  |  |  |  |  |  |
Other long-term assets |  | $ 174,000 |  | $ 174,000 |  |  |  |  |  |
Warrants outstanding | shares |  | 0 |  |  |  |  |  |  |  |
Gain (loss) on change in fair value of derivative liability |  | $ (1,250,000) | $ 464,000 |  |  |  |  |  |  |
Number of operating segments | Segment |  | 1 |  |  |  |  |  |  |  |
BioPharma Debt |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum repayment of future revenue and receivables |  | $ 134,600,000 |  |  |  |  |  |  |  | $ 150,000,000
Fair value of embedded derivative liability |  |  |  |  |  |  |  |  |  | $ 14,600,000
Gain (loss) on change in fair value of derivative liability |  | (400,000) | 0 |  |  |  |  |  |  |
Preferred Stock Purchase Option |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Gain (loss) on change in fair value of derivative liability |  |  | (946,000) |  |  |  |  |  |  |
Derivative liability at fair value |  |  |  |  |  | $ 900,000 |  |  |  |
Embedded Derivative Financial Instruments |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Gain (loss) on change in fair value of derivative liability |  | (1,250,000) | $ 1,300,000 |  |  |  |  |  |  |
Embedded Derivative Financial Instruments | BioPharma Debt |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum repayment of future revenue and receivables |  |  |  |  |  |  |  |  | $ 150,000,000 |
Fair value of embedded derivative liability |  | 5,900,000 |  | 5,500,000 |  |  |  |  |  |
Gain (loss) on change in fair value of derivative liability |  | $ (400,000) |  |  |  |  |  |  |  |
Top Three Customers | Gross Product Sales | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  | 95.00% | 94.00% |  |  |  |  |  |  |
Top Three Customers | Accounts Receivable | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  | 95.00% | 94.00% |  |  |  |  |  |  |
Convertible Debt | 2014 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Convertible senior notes, discount |  |  |  |  |  |  |  | $ 27,900,000 |  |
Fair value of embedded derivative liability |  | $ 2,800,000 |  | 2,100,000 |  |  |  |  |  |
Gain (loss) on change in fair value of derivative liability |  | (700,000) | $ 1,300,000 | (700,000) |  |  |  |  |  |
Derivative liability at fair value |  |  |  |  |  |  |  | $ 3,500,000 |  |
Convertible Debt | 2015 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Convertible senior notes, discount |  |  |  |  | $ 3,800,000 |  |  |  |  |
Fair value of embedded derivative liability |  | 700,000 |  | 600,000 |  |  |  |  |  |
Gain (loss) on change in fair value of derivative liability |  | $ (100,000) |  | $ (100,000) |  |  |  |  |  |
Derivative liability at fair value |  |  |  |  | $ 500,000 |  |  |  |  |
Convertible Debt | 2014 Notes and 2015 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Derivative liability fair value assumptions, dividend yield |  | 27.70% |  | 25.60% |  |  |  |  |  |
Derivative liability fair value assumptions, risk-free rate |  | 2.40% |  | 2.90% |  |  |  |  |  |
Derivative liability fair value assumptions, volatility rate |  | 90.00% |  | 89.00% |  |  |  |  |  |
Convertible Debt | 2012 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Convertible senior notes, discount |  | $ 0 |  | $ 0 |  |  |  |  |  |
Note, expected term | 24 months |  |  |  |  |  |  |  |  |
Non Cash | Convertible Debt | 2014 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Convertible senior notes, discount |  | 22,500,000 |  | 24,100,000 |  |  |  |  |  |
Non Cash | Convertible Debt | 2015 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Convertible senior notes, discount |  | $ 3,900,000 |  | $ 4,200,000 |  |  |  |  |  |
Warrants Issued October 2009 |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Warrants outstanding | shares |  | 0 |  | 0 |  |  | 8,087,388 |  |  |
Warrants exercised | shares |  |  | 1,844,585 |  |  |  |  |  |  |
Warrants expired | shares |  |  | 6,242,803 |  |  |  |  |  |  |
Accounting Standards Update 2015-03 | Scenario, Adjustment |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Other long-term assets |  |  |  | $ (1,900,000) |  |  |  |  |  |
Unamortized debt issuance cost |  |  |  | $ 1,900,000 |  |  |  |  |  |
Minimum | Embedded Derivative Financial Instruments | BioPharma Debt |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Derivative liability fair value assumptions, term |  | 1 year 9 months 18 days |  | 2 years |  |  |  |  |  |
Derivative liability fair value assumption, coupon rate |  | 6.60% |  | 6.60% |  |  |  |  |  |
Derivative liability fair value assumptions, market yields |  | 12.30% |  | 13.00% |  |  |  |  |  |
Maximum | Embedded Derivative Financial Instruments | BioPharma Debt |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Derivative liability fair value assumptions, term |  | 7 years 1 month 6 days |  | 7 years 3 months 18 days |  |  |  |  |  |
Derivative liability fair value assumption, coupon rate |  | 12.50% |  | 12.50% |  |  |  |  |  |
Derivative liability fair value assumptions, market yields |  | 25.10% |  | 30.70% |  |  |  |  |  |

X
- Definition Accounts Receivable Credit Period + References No definition available. + Details
Name: | amrn_AccountsReceivableCreditPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash Discount Invoice Terms + References No definition available. + Details
Name: | amrn_CashDiscountInvoiceTerms
Namespace Prefix: | amrn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash Discount Percent + References No definition available. + Details
Name: | amrn_CashDiscountPercent
Namespace Prefix: | amrn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Class of Warrant or Right, Exercised in Period + References No definition available. + Details
Name: | amrn_ClassOfWarrantOrRightExercisedInPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Class of Warrant or Right, Expired in Period + References No definition available. + Details
Name: | amrn_ClassOfWarrantOrRightExpiredInPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Assumptions, Comparable Yield to Maturity + References No definition available. + Details
Name: | amrn_FairValueAssumptionsComparableYieldToMaturity
Namespace Prefix: | amrn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Assumptions Coupon Rate + References No definition available. + Details
Name: | amrn_FairValueAssumptionsCouponRate
Namespace Prefix: | amrn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Private Placement Issuance Number Of Tranches + References No definition available. + Details
Name: | amrn_PrivatePlacementIssuanceNumberOfTranches
Namespace Prefix: | amrn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Significant Accounting Policies [Line Items] + References No definition available. + Details
Name: | amrn_SignificantAccountingPoliciesLineItems
Namespace Prefix: | amrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Write Offs Of Accounts Receivables + References No definition available. + Details
Name: | amrn_WriteOffsOfAccountsReceivables
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_DebtInstrumentTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400 + Details
Name: | us-gaap_DebtInstrumentUnamortizedDiscount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 20 -Section 50 -Paragraph 4D -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=51814546&loc=SL51823488-111719 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226000-175313 + Details
Name: | us-gaap_DerivativeFairValueOfDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959 + Details
Name: | us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedDividendRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Risk-free interest rate assumption used in valuing an instrument. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsRiskFreeInterestRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherAssetsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_UnamortizedDebtIssuanceExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 + Details
Name: | us-gaap_UnrealizedGainLossOnDerivatives
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=amrn_TopThreeCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoAndThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=amrn_NonCashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201503Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |